Rohto Pharmaceutical Co., Ltd. is a leading Japanese manufacturer specializing in pharmaceutical products, cosmetics, and functional foods. Founded in 1899 and headquartered in Osaka, the company is recognized for its comprehensive health and beauty portfolio, with a particular prominence in eye care products such as eye drops, contact lens solutions, and related ophthalmic medicines. Rohto also develops and markets a broad range of skincare items, including creams, lotions, sunscreens, and dermatological treatments, along with digestive and herbal medicines, over-the-counter remedies, and diagnostic kits. With operations spanning Japan, the Americas, Europe, and Asia, Rohto Pharmaceutical holds a significant presence in both domestic and international markets. The company plays a pivotal role in the consumer non-cyclicals sector, notably in personal care and household products, and is also engaged in contract development and manufacturing, as well as investment management services. Through ongoing innovation and a diversified product lineup, Rohto Pharmaceutical Co., Ltd. serves a wide array of health and wellness needs globally, reinforcing its longstanding reputation within the pharmaceutical and personal care industries.
Industry
Household & Personal Products
Consumer Defensive sector · Japan
Stories
Structural patterns identified in Rohto Pharmaceutical Co., Ltd.
No stories identified yet.
Key Metrics
Market Capitalization
571.80BJPY
NormalMar 18, 2026
Trailing P/E
15.38JPY
NormalMar 18, 2026
Revenue (TTM)
335.80BJPY
NormalMar 18, 2026
Forward Yield
1.76%
Above 5Y avg (1.03%)
Annual Rate
JPY 42.00
Paid semi-annual
Payout Ratio
26.4%
Sustainable
Loading dividend history...
Track Record
Frequency
Semi-Annual
Upcoming
Ex-Dividend Date
Mar 30, 2026
Valuation9
Market Capitalization
571.80BJPY
NormalMar 18, 2026
Enterprise Value
540.34BJPY
NormalMar 18, 2026
Trailing P/E
15.38JPY
Coordination
Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination
Profit Margin
10.29%
Normal
Mar 18, 2026
Beta
-0.5520JPY
BelowNormalMar 18, 2026
52-Week Change
6.92JPY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
1.76%
NormalMar 18, 2026
Normal
Mar 18, 2026
Forward P/E
14.30JPY
NormalMar 18, 2026
PEG Ratio
14.30JPY
ExtremeMar 18, 2026
Price to Sales (TTM)
1.61JPY
NormalMar 18, 2026
Price to Book (MRQ)
1.88JPY
NormalMar 18, 2026
Enterprise to Revenue
1.61JPY
NormalMar 18, 2026
Enterprise to EBITDA
9.55JPY
NormalMar 18, 2026
Profitability & Growth62
Profit Margin
10.29%
NormalMar 18, 2026
Operating Margin
15.88%
NormalMar 18, 2026
Return on Assets (TTM)
0.0580JPY
NormalMar 18, 2026
Return on Equity (TTM)
0.1220JPY
NormalMar 18, 2026
Revenue (TTM)
335.80BJPY
NormalMar 18, 2026
Revenue per Share (TTM)
1.48KJPY
NormalMar 18, 2026
Quarterly Revenue Growth
0.0230JPY
NormalMar 18, 2026
Gross Profit (TTM)
188.49BJPY
NormalMar 18, 2026
EBITDA
54.85BJPY
ExtremeMar 18, 2026
Net Income (TTM)
34.54BJPY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
-0.1060JPY
NormalMar 18, 2026
Operating Cash Flow (TTM)
36.82BJPY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
31.01BJPY
NormalMar 18, 2026
Forward Annual Dividend Rate
42.00JPY
AboveNormalMar 18, 2026
Forward Annual Dividend Yield
1.76%
NormalMar 18, 2026
Trailing Annual Dividend Rate
41.00JPY
AboveNormalMar 18, 2026
Trailing Annual Dividend Yield
1.72%
NormalMar 18, 2026
5-Year Average Dividend Yield
103.00%
ExtremeMar 18, 2026
Payout Ratio
0.2640JPY
NormalMar 18, 2026
Minority Interest (Equity)
11.35B
NormalFY2025 · Mar 31, 2025
Revenue
308.63B
NormalFY2025 · Mar 31, 2025
Cost of Goods Sold
133.69B
NormalFY2025 · Mar 31, 2025
Gross Profit
174.94B
NormalFY2025 · Mar 31, 2025
Operating Income
38.94B
NormalFY2025 · Mar 31, 2025
Pre-tax Income
42.33B
NormalFY2025 · Mar 31, 2025
Income Tax Expense
11.38B
NormalFY2025 · Mar 31, 2025
Net Income
30.95B
NormalFY2025 · Mar 31, 2025
EBIT
43.28B
NormalFY2025 · Mar 31, 2025
ebitda-income
54.85B
NormalFY2025 · Mar 31, 2025
Research & Development
14.91B
NormalFY2025 · Mar 31, 2025
Selling, General & Administrative
57.51B
NormalFY2025 · Mar 31, 2025
Other Operating Expenses
31.05B
NormalFY2025 · Mar 31, 2025
Non-operating Interest Income
1.22B
NormalFY2025 · Mar 31, 2025
Non-operating Interest Expense
949.00M
NormalFY2025 · Mar 31, 2025
EPS (Basic)
136.11
AboveNormalFY2025 · Mar 31, 2025
EPS (Diluted)
135.44
AboveNormalFY2025 · Mar 31, 2025
Basic Shares Outstanding
227.80MShares
NormalFY2025 · Mar 31, 2025
Diluted Shares Outstanding
227.80MShares
NormalFY2025 · Mar 31, 2025
Net Income from Continuing Operations
42.33B
NormalFY2025 · Mar 31, 2025
Minority Interests (P&L)
54.00M
NormalFY2025 · Mar 31, 2025
Preferred Stock Dividends
0.00
NormalFY2025 · Mar 31, 2025
Operating Cash Flow
36.82B
NormalFY2025 · Mar 31, 2025
Free Cash Flow
26.36B
NormalFY2025 · Mar 31, 2025
Cash & Cash Equivalents (End of Period)
73.22B
NormalFY2025 · Mar 31, 2025
Net Income (CF Statement)
42.33B
NormalFY2025 · Mar 31, 2025
Other Non-cash Items
-2.86B
NormalFY2025 · Mar 31, 2025
Change in Accounts Receivable (CF)
1.95B
NormalFY2025 · Mar 31, 2025
Change in Other Assets/Liabilities
-4.60B
NormalFY2025 · Mar 31, 2025
Capital Expenditures
-9.05B
NormalFY2025 · Mar 31, 2025
Net Intangibles (CF)
-1.48B
NormalFY2025 · Mar 31, 2025
Net Acquisitions
-74.48B
NormalFY2025 · Mar 31, 2025
Purchase of Investments
-9.54B
NormalFY2025 · Mar 31, 2025
Sale of Investments
5.97B
NormalFY2025 · Mar 31, 2025
Other Investing Activity
163.00M
NormalFY2025 · Mar 31, 2025
Net Investing Cash Flow
-86.93B
NormalFY2025 · Mar 31, 2025
Long-term Debt Issuance
40.18B
NormalFY2025 · Mar 31, 2025
Long-term Debt Payments
-5.96B
NormalFY2025 · Mar 31, 2025
Net Short-term Debt Issuance
-2.31B
NormalFY2025 · Mar 31, 2025
Common Stock Repurchase
-5.00B
NormalFY2025 · Mar 31, 2025
Common Dividends Paid
-7.07B
NormalFY2025 · Mar 31, 2025
Other Financing Charges
15.48B
NormalFY2025 · Mar 31, 2025
Net Financing Cash Flow
35.32B
NormalFY2025 · Mar 31, 2025
Financial Strength28
Shares Outstanding
225.96MShares
NormalMar 18, 2026
Float Shares
200.75MJPY
NormalMar 18, 2026
% Held by Insiders
0.0969JPY
NormalMar 18, 2026
% Held by Institutions
0.3714JPY
NormalMar 18, 2026
Total Cash (MRQ)
74.10BJPY
NormalMar 18, 2026
Total Cash per Share (MRQ)
327.92JPY
NormalMar 18, 2026
Total Debt (MRQ)
51.79BJPY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
16.99JPY
AboveNormalMar 18, 2026
Current Ratio (MRQ)
2.03JPY
NormalMar 18, 2026
Book Value per Share (MRQ)
1.27KJPY
AboveNormalMar 18, 2026
Total Assets
421.87B
NormalFY2025 · Mar 31, 2025
Total Current Assets
217.88B
NormalFY2025 · Mar 31, 2025
Total Liabilities
150.44B
NormalFY2025 · Mar 31, 2025
Total Non-current Assets
203.99B
NormalFY2025 · Mar 31, 2025
Total Non-current Liabilities
55.83B
NormalFY2025 · Mar 31, 2025
Total Current Liabilities
94.61B
NormalFY2025 · Mar 31, 2025
Cash & Cash Equivalents
77.16B
NormalFY2025 · Mar 31, 2025
Accounts Receivable
47.13B
NormalFY2025 · Mar 31, 2025
Inventory
61.58B
NormalFY2025 · Mar 31, 2025
Accounts Payable
19.05B
NormalFY2025 · Mar 31, 2025
Short-term Debt
7.04B
NormalFY2025 · Mar 31, 2025
Other Current Liabilities
37.20B
NormalFY2025 · Mar 31, 2025
Long-term Debt
43.19B
NormalFY2025 · Mar 31, 2025
Other Non-current Liabilities
8.79B
NormalFY2025 · Mar 31, 2025
Common Stock (Book)
6.50B
NormalFY2025 · Mar 31, 2025
Retained Earnings
228.44B
NormalFY2025 · Mar 31, 2025
Total Shareholders' Equity
271.44B
NormalFY2025 · Mar 31, 2025
Treasury Stock
9.94B
ExtremeFY2025 · Mar 31, 2025
Market & Technical9
52-Week Low
1.96KJPY
NormalMar 18, 2026
52-Week High
2.70KJPY
NormalMar 18, 2026
52-Week Change
6.92JPY
ExtremeMar 18, 2026
Beta
-0.5520JPY
BelowNormalMar 18, 2026
50-Day MA
2.50KJPY
NormalMar 18, 2026
200-Day MA
2.40KJPY
NormalMar 18, 2026
Avg 10-Day Volume
951.69KJPY
NormalMar 18, 2026
Avg 30-Day Volume
920.49KJPY
NormalMar 18, 2026
Diluted EPS (TTM)
155.40JPY
AboveNormalMar 18, 2026
Screen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.